A Federal Circuit panel on Tuesday vacated its October finding that Teva induced infringement of a patent covering GlaxoSmithKline's drug Coreg to the tune of $235 million and set a new...
Want to continue reading?
Take a 7 Day FREE Trial
Unlock these benefits today when you sign-up for a FREE 7-day trial:
- Gain a competitive edge with exclusive data visualization tools to tailor to your practice
- Stay informed with daily newsletters and custom alerts across 14+ coverage areas relevant to you
- Streamline your business of law needs with integrated news and research in a single destination
Already have an account? Sign In Now
